Clinical trials: Refractory Anemia With Excess Blasts
Hematological Malignancy, Leukemia
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients.
- Conditions
- Hematological Malignancy, Leukemia, Myelodysplasia, Lymphoma
- Trial name
- NCT00195533
- Testing
- piperacillin-tazobactam, glycopeptide
- Where
- 12 sites in Spain
- Volunteers
- 801 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Leukemia, Myelodysplastic Syndromes
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00070538
- Testing
- cytarabine, laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Myelodysplastic Syndromes
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome.
- Trial name
- NCT00017550
- Testing
- anti-thymocyte globulin
- Where
- 28 sites in United States, Canada
- Sponsor
- Genzyme, a Sanofi Company
Leukemia, Myelodysplastic Syndromes
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00020969
- Testing
- arsenic trioxide
- Where
- 8 sites in United States
- Sponsor
- CTI BioPharma
Acute Leukemia, Acute Lymphoblastic Leukemia
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain…
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT05589896
- Testing
- Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC)
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ossium Health, Inc.
Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options.
- Conditions
- Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis
- Trial name
- NCT03886831
- Testing
- PRT543
- Where
- 23 sites in United States
- Volunteers
- 232 people
- Sponsor
- Prelude Therapeutics Incorporated
Hematological Malignancies, Myelodysplasia
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies
- Conditions
- Hematological Malignancies, Myelodysplasia, Agnogenic Myeloid Metaplasia
- Trial name
- NCT00506402
- Testing
- MKC-1
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- CASI pharmaceuticals, Inc.
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients Who Have Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic…
- Trial name
- NCT00004047
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Myelodysplastic Syndromes, MDS
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
The primary objective of this study is to compare overall survival (OS) in patients receiving ON 01910.Na + best supportive care (BSC) to OS of patients receiving BSC in a population of patients with myelodysplastic syndrome…
- Conditions
- Myelodysplastic Syndromes, MDS, RAEB, Chronic Myelomonocytic Leukemia
- Trial name
- ONTIME (NCT01241500)
- Testing
- ON 01910.Na
- Where
- 87 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Traws Pharma, Inc.